Biodexa Pharmaceuticals (BDRX) Stock Statistics & Valuation Metrics

Biodexa Pharmaceuticals has a market cap or net worth of $1.31M. The enterprise value is -$6.77M.

Biodexa Pharmaceuticals has 648,314 shares outstanding. The number of shares has decreased by -2.65% in one year.

Biodexa Pharmaceuticals’s return on equity (ROE) is -0.55 and return on invested capital (ROIC) is -67.29%.

The current PE Ratio of Biodexa Pharmaceuticals is ―. Biodexa Pharmaceuticals’s PEG ratio is 0.00024.

In the last 12 months, Biodexa Pharmaceuticals had revenue of 0.00 and earned -6.24M in profits. Earnings per share was -400.00.

In the last 12 months, operating cash flow was -5.63M and capital expenditures -2.06K, giving a free cash flow of -5.63M billion.

Biodexa Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Biodexa Pharmaceuticals upcoming earnings date is Sep 11, 2026, TBA (Confirmed).

Biodexa Pharmaceuticals as a current ratio of 2.03, with Debt / Equity ratio of 0.53%

In the past 12 months, Biodexa Pharmaceuticals has paid -102.70K in taxes.

Biodexa Pharmaceuticals EV to EBITDA ratio is 1.02, with an EV/FCF ratio of 1.53.

Biodexa Pharmaceuticals has $8.52M in cash and marketable securities with $60.89K in debt, giving a net cash position of $8.46M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Biodexa Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―